Pages
Products

ODN D-SL03

For research use only. Not intended for any clinical use.
Cat.No.
CGON-19
Description
CpG oligodeoxynucleotides (or CpG ODNs) are synthetic oligonucleotides that contain unmethylated CpG motifs. CpG ODN can bind to and activate a Toll-like receptor 9 (TLR9) and leading to strong immunostimulatory effects. So far 3 major classes of CpG ODNs have been identified, based on their structural and biological characteristics, and are designated Type A, Type B, and Type C. Type A ODNs, which feature a central palindromic CpG-containing phosphodiester (PO) structure followed by a phosphorothioate (PS) homopolymeric G-stretch, are robust inducers of interferon-α (IFN-α) production and dendritic cell maturation. Type B ODNs, in contrast, contain a full phosphorothioate backbone with one or more CpG dinucleotides. They strongly activate B cells but stimulate weakly IFN-α secretion. Type C ODNs, combine the properties of both Type A and B, and are characterized by their complete PS backbone and palindromic CpG-containing motifs. Type C ODNs induce strong IFN-α production from pDC and B cell stimulation.
ODN D-SL03 is a type C CpG ODN specific for multispecies TLR9.
Features
• Classification: Type C
• Product format: Lyophilized product
• Sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' (lower case letters are phosphorothioate)
• Specificity: Multispecies
Storage
Store lyophilized product at -20°C. Upon reconstitution, aliquots should be stored at -20°C and are stable for 6 months. Avoid repeated freeze-thaw cycles.

Publications

Q & A

Customer Reviews

Customer Q&As
What is the sequence of ODN D-SL03?

A: The sequence of ODN D-SL03 is 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3'.

What is the function of ODN D-SL03?

A: ODN D-SL03 can activate human B cells, NK cells, and monocytes, upregulating the expression of CD80, CD86, and HLA-DR on human PBMC subpopulations. ODN D-SL03 can also inhibit tumor growth.

What is the concentration and exposure time for in vitro research experiments using ODN D-SL03?

A: ODN D-SL03 (0-3 μg/mL; 36 h) significantly induces IFN-α production at 0.19 μg/mL in PBMCs. ODN D-SL03 (3 μg/mL; 18 or 36 h) activates immune cells, including B, NK, T, and monocytes.

What is the dosage for in vivo studies using ODN D-SL03 in mice?

A: ODN D-SL03 (25 μg per mouse, intraperitoneal injection) results in significant inhibition of tumor growth.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Quick Inquiry

Inquiry